

# ForPatients

by Roche

Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck (SCCHN) Advanced Solid Tumors Esophageal Cancer Hepatocellular Carcinoma (HCC) Non-Small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Gastric Cancer Metastatic Solid Tumors Clear Cell Renal Cell Carcinoma Melanoma Cervical Cancer Urothelial Carcinoma

## A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

**Trial Status**  
Recruiting

**Trial Runs In**  
7 Countries

**Trial Identifier**  
NCT05581004 2021-006708-34  
GO43860

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT05581004 2021-006708-34 GO43860**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---